eligibility_summary
Include: consent, completed eligible Jasper CU trial ≤4 mo prior without IP anaphylaxis, CSU UAS7≥16 or completer, CIndU UCT≤12 or completer, labs within protocol limits, no blood donation, contraception: men use highly effective + no sperm donation +8 mo postdose, women use highly effective +90 d postdose or be sterile/menopausal. Exclude: other interventional tx, urticaria mimics, pregnancy/lactation, hypersensitivity/prior IP-related SAEs, other high-risk conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 2 open-label extension in chronic urticaria (CSU and CIndU) evaluating briquilimab (JSP191). Drug/intervention: Briquilimab, a humanized monoclonal antibody (IgG) given subcutaneously. Mechanism of action: Targets CD117 (c‑Kit), the receptor for stem cell factor (SCF). By blocking SCF–c‑Kit signaling, it depletes/inhibits KIT+ cells, especially tissue mast cells (and hematopoietic stem/progenitor cells), reducing mast cell survival and activity. Cells/pathways targeted: Mast cells expressing CD117, SCF–c‑Kit survival/activation pathway, consequent reduction in histamine and mediator release and indirect dampening of IgE/FcεRI-driven degranulation central to urticaria pathology.